PT - JOURNAL ARTICLE AU - Ibrahim O. Yekinni AU - Tom Viker AU - Ryan Hunter AU - Aaron Tucker AU - Sarah Elfering AU - Michelle N. Rheault AU - Arthur Erdman TI - Design and proof-of-concept evaluation of a touchless connector system for preventing peritoneal dialysis-associated peritonitis AID - 10.1101/2021.09.20.21263563 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.20.21263563 4099 - http://medrxiv.org/content/early/2021/09/23/2021.09.20.21263563.short 4100 - http://medrxiv.org/content/early/2021/09/23/2021.09.20.21263563.full AB - Introduction In this paper, we describe the design of a touchless peritoneal dialysis connector system and how we evaluated its potential for preventing peritoneal dialysis-associated peritonitis, in comparison to the standard of care. The unique feature of this system is an enclosure within which patients can connect and disconnect for therapy, protecting their peritoneal catheters from touch or aerosols.Methods We simulated a worst-case contamination scenario by spraying 40mL of a standardized inoculum [1×107 colony-forming units (CFU) per milliliter] of test organisms, Staphylococcus epidermidis ATCC1228 and Pseudomonas aeruginosa ATCC39327, while test participants made mock connections for therapy. We then compared the incidence of fluid path contamination by test organisms in the touchless connector system and the standard of care. 4 participants were recruited to perform a total of 56 tests, divided in a 1:1 ratio between both systems. Peritoneal dialysis fluid sample from each test was collected and maintained at body temperature (37° C) for 16 hours before being plated on Luria Bertani agar, Mannitol Salts Agar and Pseudomonas isolation agar for enumeration.Results No contamination was observed in test samples from the touchless connector system, compared to 65%, 75% and 70% incidence contamination for the standard of care on Luria Bertani agar, Mannitol Salts Agar and Pseudomonas isolation agar respectively.Conclusion Results show that the touchless connector system can prevent fluid path contamination even in heavy bacterial exposures and may help reduce peritoneal dialysis-associated peritonitis risks from inadvertent contamination with further development.SUMMARY BOXWhat are the new findings?What are the new findings?We describe the design and evaluation of a touchless peritoneal dialysis connector system showing reduced incidence of bacterial contamination in comparison to the standard of care.How might it impact on healthcare in the future?How might it impact on healthcare in the future?Integrating the touchless connector system into peritoneal dialysis systems may help reduce peritonitis risks in patients.Competing Interest StatementIOY, AT and TV invented the touchless connector. TV is an employee of Cerovations LLC, a company that has licensed the connector from the University of Minnesota for commercialization.Funding StatementResearch reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (Award Number: DK126586); National Science Foundation Division of Industrial Innovation and Partnership (Award Number 1935233); National Institutes of Health National Center for Advancing Translational Sciences (Grant UL1TR002494). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Science Foundation. Additional support was provided by The Pediatric Device Innovation Consortium at the University of Minnesota. IOY was funded through the Bakken Medical Devices Center Innovation Fellowship Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate ethical and biosafety clearance was obtained from the University of Minnesota Institutional Review Board and Biosafety Committee respectively (IRB ID: STUDY00010459)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable.